Cite
HARVARD Citation
Motzer, R. et al. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial. Cancer. 126 (18), pp. 4156-4167. [Online].